top of page

Invisible Threads: The Molecular Story of Ehlers-Danlos Syndrome

By Nikki Elmi

By Nikki Elmi



Ehlers-Danlos Syndrome (EDS) is a group of rare inherited connective tissue disorders that affect the body’s ability to produce or process collagen, an essential protein that provides strength and elasticity to skin, ligaments, blood vessels, and organs.

First described by dermatologists Edvard Ehlers and Henri-Alexandre Danlos in the early 1900s, EDS has since been classified into 13 distinct subtypes based on genetic, biochemical, and clinical features. Common characteristics across these subtypes include hypermobile joints, skin hyperextensibility, and tissue fragility. Because connective tissue is ubiquitous, EDS manifests systemically, often involving the musculoskeletal, cardiovascular, and integumentary systems. Although it is considered a rare disorder, awareness of EDS has increased in recent years due to improved genetic testing and better recognition of mild or atypical presentations.


Fig 1. Cellular Mechanism


Ehlers-Danlos Syndrome originates from mutations that disrupt the synthesis, structure, or stability of collagen; the body’s key connective tissue protein. Normally, collagen formation begins in the cell nucleus, where a collagen gene is transcribed into mRNA, which then travels to the rough endoplasmic reticulum (RER) to guide the synthesis of pre-procollagen chains. These chains undergo several crucial post-translational modifications such as hydroxylation, glycosylation, and disulfide bond formation within the RER and Golgi apparatus before being secreted as procollagen molecules. Mutations that interfere with any of these steps can lead to specific subtypes of EDS.

For example, defective gene structure or stability results in abnormal collagen formation seen in vascular EDS (type IV), while deficient hydroxylation of procollagen leads to EDS type VI. Similarly, when procollagen fails to convert into mature collagen, as in EDS type VII, the fibers remain weak and unstable. Once outside the cell, collagen normally undergoes cleavage of pro-peptides and self-assembly into fibrils, followed by cross-linking that strengthens the matrix. A defect in this final crosslinking process, as seen in EDS type IX, leads to poorly formed collagen fibrils and fragile connective tissue. These molecular errors compromise the body’s ability to produce strong and resilient collagen, resulting in the hallmark symptoms of EDS; joint hypermobility, skin elasticity, and tissue fragility.


Fig 2. Neuro-Bio-Electric Stimulation


Currently, there is no cure for Ehlers-Danlos Syndrome, and treatment focuses on symptom management, injury prevention, and improving quality of life.

Management is multidisciplinary, involving physical therapy to strengthen muscles and stabilize hypermobile joints, pain management strategies, and careful wound care due to delayed healing and fragile skin.

In vascular EDS, regular cardiovascular imaging is recommended to monitor for arterial aneurysms or ruptures, and patients are advised to avoid high-impact activities or invasive procedures that could trigger vascular injury. Some studies suggest that medications such as celiprolol, a beta-blocker, may reduce the risk of arterial complications in vascular EDS, though evidence is still limited.

Preventive measures such as bracing, using assistive devices, and practicing joint-protective techniques can significantly reduce complications. Genetic counseling is also essential for affected families to understand inheritance patterns and reproductive options. Overall, treatment aims to minimize injury, manage chronic pain, and provide psychological support for living with a chronic condition.


Fig 3. Normal Knee Joint vs. Ehlers-Danlos


Ehlers-Danlos Syndrome remains a complex and under-recognized disorder, with significant variability in presentation and prognosis depending on the subtype. Although progress has been made in identifying causative genes and understanding collagen defects, hypermobile EDS (hEDS), the most common form, still lacks a known genetic marker, making diagnosis challenging. Future research should focus on identifying molecular mechanisms underlying hEDS, developing targeted therapies to correct collagen processing, and expanding clinical trials to evaluate pharmacologic agents that can strengthen connective tissue or prevent vascular events.

Advances in genetic editing and tissue engineering may also open pathways for curative interventions. Until then, multidisciplinary care and early recognition remain the cornerstone of management, improving patient outcomes and quality of life.



By Nikki Elmi


References:



Assessed and Endorsed by the MedReport Medical Review Board

 
 

©2025 by The MedReport Foundation, a Washington state non-profit organization operating under the UBI 605-019-306

 

​​The information provided by the MedReport Foundation is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. The MedReport Foundation's resources are solely for informational, educational, and entertainment purposes. Always seek professional care from a licensed provider for any emergency or medical condition. 
 

Privacy Policy

Editorial Policy

Terms & Conditions

bottom of page